poisar

Stocks · News reference

Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Fiscal.ai

Spyre Therapeutics announced its third quarter 2026 financial results, reporting a net loss of $96.1 million and providing updates on its clinical pipeline, including positive induction data for SPY003.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading